ArchPoint Investors’s AbCellera Biologics ABCL Stock Holding History

ArchPoint Investors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$903K	Hold	115,055	–	–	0.19%	55
2026 Q1	$402K	Hold	115,055	–	–	0.1%	61
2025 Q4	$393K	Hold	115,055	–	–	0.09%	67
2025 Q3	$579K	Hold	115,055	–	–	0.16%	53
2025 Q2	$395K	Hold	115,055	–	–	0.12%	58
2025 Q1	$257K	Hold	115,055	–	–	0.08%	62
2024 Q4	$337K	Hold	115,055	–	–	0.11%	57
2024 Q3	$299K	Hold	115,055	–	–	0.1%	61
2024 Q2	$341K	Hold	115,055	–	–	0.13%	60
2024 Q1	$521K	Hold	115,055	–	–	0.22%	52
2023 Q4	$657K	Hold	115,055	–	–	0.27%	35
2023 Q3	$529K	Hold	115,055	–	–	0.2%	42
2023 Q2	$743K	Hold	115,055	–	–	0.29%	39
2023 Q1	$868K	Hold	115,055	–	–	0.38%	34
2022 Q4	$1.17M	Sell	115,055 -502,158	-81%	-$5.8M	0.55%	33
2022 Q3	$6.1M	Sell	617,213 -13,113	-2%	-$144K	2.49%	12
2022 Q2	$6.71M	Buy	630,326 +169,037	+37%	+$1.43M	2.66%	11
2022 Q1	$4.5M	Hold	461,289	–	–	1.55%	18
2021 Q4	$6.6M	Hold	461,289	–	–	1.96%	15
2021 Q3	$9.24M	Buy	+461,289	New	+$8.15M	2.77%	7

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

ArchPoint Investors's ABCL Position: Q2 2026 in Review

ArchPoint Investors held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 115,055 shares worth $903K. The position accounts for 0.19% of the portfolio, ranked #55.

ArchPoint Investors first reported a position in ABCL in Q3 2021 and has held it in 20 quarters since. The position peaked at $9.24M in Q3 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

ArchPoint Investors held 115,055 shares of AbCellera Biologics worth $903K as of Q2 2026.
ArchPoint Investors left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up 0.19% of ArchPoint Investors's portfolio in Q2 2026, its #55 holding.
ArchPoint Investors first reported a position in AbCellera Biologics in Q3 2021 and has held it in 20 quarters since.
ArchPoint Investors's AbCellera Biologics position peaked at $9.24M in Q3 2021.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on ArchPoint Investors's 13F filing for Q2 2026, filed 13 Aug 2026.